Article
The role of national agencies in the managed introduction of new
drugs for arthritis
Katrina Simister
National Prescribing
Centre, 70 Pembroke Place, Liverpool L69 3GF
Correspondence to: Mrs Simister (katrina.simister{at}liverpool-ha.nhs.uk)
The role of the various agencies involved in the managed
introduction of new drugs in the United Kingdom is discussed,
particularly with regard to the work of the National Institute for
Clinical Excellence (NICE). The process by which the National Health
Service in the UK identifies key new drug technologies of major
clinical, financial and service significance is discussed. This
includes the decision making process for selection of products for
appraisal by NICE. The appraisal procedure and the impact of NICE
guidance for the NHS will, it is hoped, encourage quality in clinical
practice. All healthcare systems face budgetary constraints and the
introduction of new technologies bring particular challenges. The
launch of the new biological agents for the treatment of rheumatoid
arthritis, into a speciality where previously relatively inexpensive
agents were prescribed, raises questions concerning managed
introduction and re-imbursement.
© 2000 by Annals of the Rheumatic Diseases
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
